אנגרליד אורפא - Anagrelide orpha
ש××× ×× !
×תר××¤× × ×¢××× ×:×××ר ×תר×פ×ת ×©× ××©×¨× ××ר×××ת.
×× ×תק××× ××××¢× ×¢× ×פסקת ש×××ק ×תר××¤× ×:×ער×ת ×××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת.
ת×ר×× ×¢×××× ××ר×× ×תר××¤× ×× ×××ק×תר×פ×ת ××× 04/02/17.
×תר××¤× × ×¢××× ×:×××ר ×תר×פ×ת ×©× ××©×¨× ××ר×××ת.
×× ×תק××× ××××¢× ×¢× ×פסקת ש×××ק ×תר××¤× ×:×ער×ת ×××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת.
ת×ר×× ×¢×××× ××ר×× ×תר××¤× ×× ×××ק×תר×פ×ת ××× 04/02/17.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XX Other antineoplastic agents | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | *Anagrelide AS HYDROCHLORIDE 0.5MG âL01XX35 | |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | קפס××× ×§×©×××, HARD CAPSULE ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Anagrelide Orpha is indicated for the reduction of an increased platelet number and associated clinical symptoms in high risk patients with Essential Thrombocythemia.High risk patient with essential thrombocythemia show one or more following symptoms: â¢Age >= 60 ⢠Platelet count > = 1.000.000/ µl-Increase of platelet count >= 300.000/ µl within 3 month- Severe thrombohaemorrhagic or ischaemic symptoms in anamnesis- Vascular risk factors
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| [ ×× ×ר××× ××רפ×] ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | AOP ORPHAN PHARMACEUTICALS AG, AUSTRIA |
| ×©× ××¢× ×ר×ש×× | TRUEMED LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 10/2011. ר×ש××× ×ת×ר××: 03/2012 |
| ת×ר×× ×¢×××× ××ר×× | 04/02/17 |